{
    "clinical_study": {
        "@rank": "127665", 
        "arm_group": [
            {
                "arm_group_label": "Ozurdex implant up to every 3 months", 
                "arm_group_type": "Active Comparator", 
                "description": "Ozurdex (Dexamethasone) 0.7 mg implant will be performed on Day 0.  All patients will be evaluated monthly thereafter.\nIntervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.\nRe-implantation of Ozurdex may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:\nIncrease of > 50 microns from the best previous CRT measurement\nRecurrence of intraretinal cystic edema\nPersistent intraretinal cystic edema"
            }, 
            {
                "arm_group_label": "Ozurdex implant up to every 6 months", 
                "arm_group_type": "Active Comparator", 
                "description": "Ozurdex (Dexamethasone) 0.7 mg implant will be performed on Day 0.  All patients will be evaluated monthly thereafter.\nIntervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.\nRe-implantation of Ozurdex may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:\nIncrease of > 50 microns from the best previous CRT measurement\nRecurrence of intraretinal cystic edema\nPersistent intraretinal cystic edema"
            }, 
            {
                "arm_group_label": "Sham Implant", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham Procedure will be performed on Day 0.  All patients will be evaluated monthly thereafter.\nIntervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.  Also, at 13 months, patients in the sham group will be eligible for Ozurdex (Dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met.  These patients would follow re-implantation guidelines of group 2.\nSham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:\nIncrease of > 50 microns from the best previous CRT measurement\nRecurrence of intraretinal cystic edema\nPersistent intraretinal cystic edema"
            }
        ], 
        "brief_summary": {
            "textblock": "Currently medications injected intravitreally in previously vitrectomized eyes have a very\n      short half-life due to enhanced clearance of the drug.  The use of the Ozurdex implant may\n      allow sustained levels of steroid delivery to patients with diabetic macular edema that have\n      undergone prior vitrectomy. The sustained steroid levels may lead to improved central\n      retinal thickness measurements and improved visual acuity."
        }, 
        "brief_title": "Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetic Macular Edema", 
            "DME", 
            "Pars Plana Vitrectomy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "A total of 15 patients will be enrolled into the study.  This is a 3 year randomized\n      controlled study with the primary endpoint at 1 year.  Secondary safety and efficacy\n      endpoints will be evaluated in year 2 and year 3.\n\n      Patients will be randomly enrolled into 1 of 3 groups:\n\n      Group 1:  Ozurdex administered up to every 3 months Group 2:  Ozurdex administered up to\n      every 6 months Group 3:  Sham Ozurdex\n\n      Patients will be evaluated on a monthly basis with ETDRS visual acuity, intraocular\n      pressure, fundus examination and OCT.\n\n      Ozurdex or Sham Procedure will be performed on Day 0.  All patients will be evaluated\n      monthly thereafter.  One month following initial injection/sham, patients will be evaluated\n      for focal or grid laser treatment if the investigator feels the patient will benefit.\n\n      Re-implantation of Ozurdex may occur at any time > 3 months following last injection in\n      group 1 and > 6 months following last injection in group 2 if any of the following\n      conditions are met:\n\n        1. Increase of > 50 microns from the best previous CRT measurement\n\n        2. Recurrence of intraretinal cystic edema\n\n        3. Persistent intraretinal cystic edema\n\n      At 13 months, patients in the sham group will be eligible for Ozurdex implantation if\n      initial inclusion/exclusion criteria are met.  These patients would follow re-implantation\n      guidelines of group 2 (up to every 6 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adults> 18 years of age with type 1 or 2 diabetes mellitus\n\n          2. Patients with DME secondary to diabetes mellitus involving the center of the macula\n             OCT thickness is > 300 microns with intraretinal cystic edema\n\n          3. BCVA between 20/40 to 20/400\n\n          4. Patient had vitrectomy surgery.\n\n          5. Provide a signed informed consent prior to any study procedure\n\n        Exclusion Criteria:\n\n          1. Patient unlikely to benefit from intravitreal Ozurdex due to macular ischemia,\n             atrophy, or other condition\n\n          2. Patient with history of steroid response with IOP >35 mm Hg or requirement to be on >\n             2 glaucoma medications following previous steroid injection.\n\n          3. Previous injection of anti-VEGF or steroid in the study eye within 90 days\n\n          4. Vitrectomy, cataract surgery, or YAG capsulotomy within 90 days.\n\n          5. Current tractional detachment of the macula or vitreous hemorrhage obscuring details\n             of the macula.\n\n          6. Pregnant, lactating females, or females of child-bearing potential that are not using\n             reliable contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788475", 
            "org_study_id": "2012-031"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ozurdex implant up to every 3 months", 
                "Ozurdex implant up to every 6 months", 
                "Sham Implant"
            ], 
            "description": "Ozurdex 0.7mg steroid implant", 
            "intervention_name": "Dexamethasone", 
            "intervention_type": "Drug", 
            "other_name": [
                "Ozurdex", 
                "Dexamethasone Posterior segment drug delivery system", 
                "DEX PS DDS"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetic Macular Edema", 
            "DME", 
            "Pars Plana Vitrectomy"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "location": {
            "contact": {
                "email": "Avon.P.Stewart@Lahey.org", 
                "last_name": "Avon P Stewart, BS", 
                "phone": "978-538-4412"
            }, 
            "facility": {
                "address": {
                    "city": "Peabody", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01960"
                }, 
                "name": "Lahey Clinic"
            }, 
            "investigator": [
                {
                    "last_name": "Fina C Barouch, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Greg R Blaha, MD,PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jeffrey Chang, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Altin Pani, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jeffrey L Marx, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Pilot Study of the Efficacy and Safety of Ozurdex Steroid Implants in Post-Vitrectomized Eyes in Patients With Diabetic Macular Edema", 
        "other_outcome": [
            {
                "description": "VA gain in ETDRS letters at years 2 and 3", 
                "measure": "Visual Acuity gain at year 2 and 3", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Time in months until new implant is needed", 
                "measure": "Time to reimplantation of Ozurdex Implant", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Comparison of efficacy between group 1 and 2", 
                "measure": "Comparison of efficacy between group 1 and 2", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "overall_contact": {
            "email": "avon.p.stewart@lahey.org", 
            "last_name": "Avon P Stewart", 
            "phone": "978-538-4412"
        }, 
        "overall_official": [
            {
                "affiliation": "Lahey Clinic", 
                "last_name": "Fina C Barouch, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Lahey Clinic", 
                "last_name": "Jeffrey L Marx, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured visual acuity gain in number of letters improved as a result of treatment", 
            "measure": "Visual Acuity Gain", 
            "safety_issue": "No", 
            "time_frame": "13 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788475"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lahey Clinic", 
            "investigator_full_name": "Jeffrey L. Marx, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Central Retinal Thickness Reduction as measured by Heidelberg OCT", 
            "measure": "Central retinal Thickness Reduction", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Lahey Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lahey Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}